HHS Finally Ends Long-Running COVID Emergency Drug Rules
Published Date: 7/2/2026
Notice
Summary
The U.S. Department of Health and Human Services is ending the special emergency rules that allowed quick use of COVID-19 drugs and vaccines. This change affects companies, healthcare workers, and patients who relied on these emergency approvals. The emergency use authorization will officially stop on June 29, 2027, giving everyone time to adjust without sudden disruptions or extra costs.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
EUA Declaration Ends June 29, 2027
The special HHS declaration that allowed Emergency Use Authorizations (EUAs) for COVID-19 drugs and biological products will terminate effective June 29, 2027. This ends the legal basis for issuing new EUAs under that declaration and affects companies, healthcare workers, and patients who relied on EUA-authorized products.
12-Month Transition: No New EUA Reviews
HHS is providing 12 months' advance notice and FDA has decided it will decline to review or process any new EUA requests for COVID-19 drugs or biological products during that 12-month transition period. FDA will only review EUA amendments during that period if they are necessary to protect public health (for example, labeling changes for drug interactions or updated variant susceptibility data).
Path to Full Approval and Access Options
FDA is encouraging sponsors of EUA products to seek full approval by submitting New Drug Applications (NDAs) or Biologics License Applications (BLAs), and says the 12-month transition period is a reasonable time for sponsors to generate data to support such submissions. If a gap exists between the end of an EUA and FDA approval, sponsors can work with FDA to maintain access through clinical trials and expanded access protocols, and FDA will consult with manufacturers about disposition of unapproved products.
Some COVID-19 EUAs Revoked; Products Licensed
The notice states that EUAs for COVID-19 vaccines and convalescent plasma have already been revoked and that there are now COVID-19 vaccines and convalescent plasma products licensed through traditional Biologics License Applications (BLAs). The FDA also says there are FDA-approved therapeutic options available for all ages and across the spectrum of disease.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-22812, Medicare and Medicaid Programs; Cutting Administrative Requirements for Excellence in Patient Care
CMS is proposing to cut outdated and tricky rules in Medicare and Medicaid to help doctors and nurses spend more time caring for patients instead of paperwork. These changes aim to save money, boost flexibility, and make healthcare better and easier to manage. Comments on this plan are open until January 11, 2027, so everyone affected can share their thoughts!
2026-22792, Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program
Starting in 2029, Medicare will negotiate drug prices to help lower costs for people using Medicare Part D. This new rule, effective December 5, 2026, sets clear policies to make prescription drugs more affordable and fair. If you or a loved one uses Medicare for prescriptions, expect some savings and changes in how drug prices are set.
2026-22750, Calendar Year 2027 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the Expanded HH Value-Based Purchasing Model; Medicare Provider Enrollment, Durable Medical Equipment (DME), and DME, Prosthetics, Orthotics, and Supplies (DMEPOS) Policies
Starting in 2027, Medicare is updating how it pays home health agencies, including new payment rates and rules to make care better and fairer. Home health providers, equipment suppliers, and Medicare enrollees will see changes in payment methods, quality reporting, and equipment rules, with some new deadlines and expanded benefits. These updates aim to improve care quality while keeping payments clear and fair.
2026-22743, Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program
Starting January 1, 2027, Medicare and Medicaid are updating how doctors and clinics get paid to better match real medical work and new laws. This includes new rules for drug price rebates, sharing savings programs, and payment updates for rural clinics and ambulance services. These changes affect doctors, patients, and healthcare providers, aiming to keep care fair, affordable, and up-to-date.
2026-22739, Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data; Prior Authorization; Accrediting Organization (AO) Deeming for Emergency Medical Treatment and Labor Act (EMTALA); and Notices of Closure of Teaching Hospitals and Opportunities To Apply for Available Slots
Starting in 2027, Medicare is updating how hospitals and surgery centers get paid for outpatient care and surgeries. These changes affect hospitals, surgery centers, and patients by adjusting payment rates and improving quality reporting. Plus, CMS is asking for ideas to make hospital price info clearer and easier to compare, while also handling rules about emergency care and teaching hospital closures.
2026-22381, Medicare and Medicaid Programs; Organ Procurement Organizations Conditions for Coverage: Revisions to the Conditions for Coverage
This new rule updates how Organ Procurement Organizations (OPOs) operate to help get more life-saving organs to people who need transplants. It changes some definitions, competition rules, and appeal processes to make OPOs work better and be held accountable. These changes start January 4, 2027, and aim to save more lives without adding extra costs.
Previous / Next Documents
Previous: 2026-13373, Termination of Three Declarations Authorizing Emergency Use of Medical Devices During the COVID-19 Pandemic
The U.S. Department of Health and Human Services is ending the emergency use authorizations for certain COVID-19 medical devices, including tests and masks, on December 26, 2026. This change affects manufacturers, healthcare providers, and anyone using these devices, signaling a return to normal rules and regulations. No emergency use means these products will now follow regular approval processes, with no extra emergency funding involved.
Next: 2026-13376, Initiation of Five-Year (Sunset) Reviews
The U.S. Department of Commerce is kicking off its automatic five-year checkup on certain trade duties to see if they should stay or go. This affects companies importing products like ironing tables and magnesia carbon from countries like China. Starting July 2, 2026, these reviews could impact prices and trade rules, so businesses should stay alert!